Joint statement offers new recommendations for treating cardiovascular conditions
the ONA take:
A new scientific statement issued jointly by the American Heart Association, American College of Cardiology, and American Society of Hypertension addresses treatment goals for patients with high blood pressure who also have vascular diseases.
The statement acknowledges that a target blood pressure of less than 140/90 mm Hg is reasonable to reduce the risk of heart attacks and strokes in the general population, a lower target of less than 130/80 mm Hg may be appropriate for some patients with heart disease who have already experienced a stroke, heart attack, or mini-stroke (transient ischemic attack [TIA]).
Additional recommendations and contraindications include which antihypertensives to use in patients with various types of heart disease. The statement also recommends lowering blood pressure slowly in patients with coronary artery blockages.
Furthermore, clinicians should not strive to lower the diastolic number to less than 60 mm Hg, especially in patients older than 60 years.
These recommendations also reiterate the importance of modifying other risk factors, including abdominal obesity, abnormal cholesterol, diabetes, and smoking.
New statement addresses treatment goals for patients with high blood pressure who also have vascular diseases.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Molecular Features May Predict Response in Primary Pancreatic Cancer
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Clinical Characteristics That Increase Risk of Chemotherapy-Induced Febrile Neutropenia Identified
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Counseling Patients on Oral Chemotherapy
- Patients and Caregivers Worry About Cost of Cancer Care
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|